Sexual Health, Lack of Libido

References:

  • Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999, 281:537-544.
  • Berman J, Berman L: For Women Only. New York: Henry Holt and Company; 2001. Comprehensive book about female sexual dysfunction that is informative for health care providers caring for women, and for women who have sexual dysfunction. The book is written using terminology that anyone can understand. It provides historical facts, physiological explanations, definitions and causes, and treatment regarding female sexual dysfunction.
  • Dubovsky SL, Buzan R: Mood Disorders. In Textbook of Psychiatry. Edited by Hales RE, Yudofsky S, Talbott J. Washington, DC: American Psychiatric Press, Inc.; 1999:479-565.
  • Casper RC, Redmond DE, Katz MM, et al.: Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression. Archives of General Psychiatry 1985, 42:1098-1104.
  • Rothschild AJ: Sexual side effects of antidepressants. Journal of Clinical Psychiatry 2000, 61:28-36.
  • Baldwin DS, Thomas SC: Depression and Sexual Function. London: Martin Dunitz; 1996.
  • Monteiro WO, Noshirvani HF, Marks IM, et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. British Journal of Psychiatry 1987, 151:107-112.
  • Clayton AH: Recognition and assessment of sexual dysfunction associated with depression. Journal of Clinical Psychiatry 2001, 62:5-9.
  • Montejo AL, Llorca G, Izquierdo JA, et al.: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry 2001, 62:10-21. A large study that compares the incidence of sexual dysfunction among different anitdepressants, and reports that there is a significant difference. These findings can help guide health care providers when choosing an antidepressant for patients.
  • Hirschfeld MD: Care of the sexually active depressed patient: Journal of Clinical Psychiatry 1999, 60:32-35.
  • Shen WW, Urosevich Z, Clayton DO: Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Journal of Reproductive Medicine 1999, 44:535-542. Sildenafil is FDA-approved only for male erectile disorder; however, this paper addresses its benefit in reversing female sexual dysfunction. Furthermore, it provides a thorough explanation of the mechanism of SSRI-induced sexual dysfunction.
  • Zajecka J: Strategies for the treatment of antidepressant-related sexual dysfunction. Journal of Clinical Psychiatry 2001, 62:35-43.
  • Herman JB, Brotman AW, Pollack MH, et al.: Fluoxetine-induced sexual dysfunction. Journal of Clinical Psychiatry 1990, 51:25-27.
  • Montejo-Gonzalez AL, Llorca G, Izuierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, setraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sexual Marital Therapy 1997, 23:176-194.
  • Reimherr FW, Amsterdam JD, Quitkin FM, et al.: Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry 1994, 55:25-31.
  • Dunner DL: Acute and maintenance treatment of chronic depression. Journal of Clinical Psychiatry 2001, 62:10-16.
  • Moore BE, Rothschild AJ: Treatment of antidepressant-induced sexual dysfunction. Hospital Practice 1999, 34:89-96.
  • Rothschild AJ: Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. American Journal of Psychiatry 1995, 152:1514-1516.
  • Shrivastava RK, Shrivastava S, Overweg N, et al.: Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 1995, 15:83-84.
  • Norden MJ: Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 1994, 2:109-112.
  • Michelson D, Bancroft J, Targum S, et al.: Female sexual dysfunction associated with antidepressant administration: A randomized placebo-controlled study of pharmacologic intervention. American Journal of Psychiatry 2000, 157:239-243. Buspirone, amantadine, and placebo were all found to ameliorate antidepressant-associated sexual dysfunction, and there were no significant differences in effectiveness between the three groups. This study suggests the importance of placebo-controlled trials for this condition.
  • Clayton AH, McGarvey EL, Abouesh AI, et al.: Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. Journal of Clinical Psychiatry 2001, 62:185-190. Sexual functioning improved when bupropion was used as an antidote (SSRI plus bupropion) and when the SSRI was discontinued, and only bupropion was used. This study addresses two important treatment strategies for SSRI-induced sexual side effects: pharmacologic antidote and switching antidepressants. It also reports patients intolerance of combined side effects and new side effects related to bupropion.
  • Masand PS, Ashton AK, Gupta S, et al.: Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. American Journal of Psychiatry 2001, 158:805-807.
  • Farah A: Relief of SSRI-induced sexual dysfunction with mirtazapine treatment. Journal of Clinical Psychiatry 1999, 60:260-261.
  • Cohen AF, Bartlick BD: Gingko biloba for antidepressant-induced sexual dysfunction. Journal of Sexual Marital Therapy 1998, 24:139-143.
  • Woodrum ST, Brown CS: Management of SSRI-induced sexual dysfunction. Annals of Pharmacotherapy 1998, 32: 1209-1215.
  • Coleman E, Gratzer T, Nesvacil L, et al.: Nefazadone and the treatment of nonparaphilic compulsive sexual behavior: A retrospective study. Journal of Clinical Psychiatry 2000, 61:282-284.
  • Berman JR, Berman LA, Lin H, et al.: Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. Journal of Sex & Marital Therapy 2001, 27:411-420.
  • Caruso S, Intelisano G, Lupo L, et al.: Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001, 108:623-628. Fifty-one women affected by arousal disorder were placed on either 25 mg of sildenafil, 50 mg of sildenafil, or placebo. Arousal and orgasm significantly improved within the sildenafil-treated groups as compared to the placebo group. This study, in addition to other studies in progress, implicate the importance of sildenafil as a treatment for female sexual dysfunction.
  • Walker PW, Cole JO, Gardner EA, et al.: Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Journal of Clinical Psychiatry 1993, 54:459-465.
  • Ferguson JM, Shrivastava RK, Stahl SM, et al.: Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Journal of Clinical Psychiatry 2001, 62:24-29. Patients with sexual dysfunction related to sertraline entered a 1-week washout period, and then were randomly assigned to sertraline or nefazodone. The majority of patients on nefazodone experienced less reemergence of sexual side effects and reported continued antidepressant activity. This study is a double-blind, randomized trial with significant results.
  • Gelenberg AJ, Laukes C, McGahuey C, et al: Mirtazapine substitution in SSRI-induced sexual dysfunction. Journal of Clinical Psychiatry 2000, 61:356-360.
  • Banov MD: Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction. Journal of Clinical Psychiatry 1999, 60:866-868.

Additional resources on female sexuality are available from MayoClinic.com:

http://www.mayoclinic.com/health/kegel-exercises/WO00119
http://www.mayoclinic.com/health/sexual-health/HA00035
http://www.mayoclinic.com/health/womens-health/WO00110
http://www.mayoclinic.com/health/sexual-health/HQ01363